Lucentis gets its own permanent J code: J2778

Why This Topic Matters

Drug-code changes can affect claim acceptance, unit reporting, payer loading, and reimbursement continuity. For practices treating wet AMD, understanding the update and surrounding payer context helps reduce denials and billing delays.

Article Sections

1. Coding update and implementation guidance

   Introduces the new permanent drug code and outlines general workflow considerations for adopting the change in practice systems and claims processes.

2. Payer mix and reimbursement context

   Summarizes payer distribution for age-related macular degeneration and discusses how different payer types may respond to the coding update.

3. Coverage, patient cost, and assistance resources

   Addresses broader reimbursement challenges tied to treatment cost, patient cost-sharing, and manufacturer support resources.

4. CMS commentary on Avastin and possible supply issues

   Notes CMS discussion of off-label ophthalmic use and the agency’s comments about supply-related considerations in the physician fee schedule context.